Impact of proton pump inhibitors on pathologic response rates following fluoropyrimidine‐based neoadjuvant chemotherapy in pancreatic cancer patients
Journal of Surgical Oncology · 2024
DOI: 10.1002/jso.27837 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2024. Verfasst von Jessica A Steadman und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepatobiliary & Pancreas Surgery, Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Neoadjuvant Therapy, Proton Pump Inhibitors, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 23 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Proton pump inhibitors (PPIs) negatively impact fluoropyrimidine‐based chemotherapy efficacy in colorectal cancer. This study assessed PPI impact on major pathologic response (mPR) rates of pancreatic adenocarcinoma (PDAC) patients receiving fluoropyrimidine‐based chemotherapy.
Methods
An institutional retrospective review of resected PDAC patients receiving neoadjuvant fluoropyrimidine‐based chemotherapy (98% FOLFIRINOX) from 2011 to 2021 was conducted. Outcomes were stratified by use or nonuse of PPIs within 6 months of neoadjuvant chemotherapy initiation. Primary outcome was mPR defined as complete or near complete response.
Results
Among 540 patients included, the median age was 64 (IQR: 60–70) years, 297 (55%) were male, and 202 (37%) were PPI users. 170 (31%) patients had mPR with similar rates among PPI users and nonusers (29% vs. 33%, p = 0.38). No difference in mPR was seen between PPI users and nonusers receiving chemoradiation (35% vs. 36%, p = 0.89) or ≥8 cycles of NAC (33% vs. 36%, p = 0.55). Median OS for PPI users was 30.9 versus 31.7 months for nonusers ( p = 0.62). On multivariable analysis, PPI therapy was not associated with decreased survival.
Conclusion
PPI usage did not significantly influence mPR or OS following neoadjuvant fluoropyrimidine‐based chemotherapy in resected PDAC patients. Further analysis of all patients, not just those who underwent resection, is required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hepatobiliary & Pancreas Surgery, Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Pharmacy Cancer Care, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Jessica A Steadman, Zhaohui Jin, Cornelius A Thiels
Zitieren
APA
Steadman, J. A., Sultan, A., Day, C. N., Parish, M. A., Warner, S. G., Kendrick, M. L., Truty, M. J., Jin, Z., & Thiels, C. A. (2024). Impact of proton pump inhibitors on pathologic response rates following fluoropyrimidine‐based neoadjuvant chemotherapy in pancreatic cancer patients. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27837
Vancouver
Steadman JA, Sultan A, Day CN, Parish MA, Warner SG, Kendrick ML, et al. Impact of proton pump inhibitors on pathologic response rates following fluoropyrimidine‐based neoadjuvant chemotherapy in pancreatic cancer patients. Journal of Surgical Oncology. 2024. doi:10.1002/jso.27837
BibTeX
@article{Steadman2024,
author = {Steadman, Jessica A and Sultan, Ahmer and Day, Courtney N and Parish, Marie A and Warner, Susanne G and Kendrick, Michael L and Truty, Mark J and Jin, Zhaohui and Thiels, Cornelius A},
title = {Impact of proton pump inhibitors on pathologic response rates following fluoropyrimidine‐based neoadjuvant chemotherapy in pancreatic cancer patients},
journal = {Journal of Surgical Oncology},
year = {2024},
doi = {10.1002/jso.27837}
}
EUVIMED